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The United Kingdom Joint Committee on Vaccination and Immunisation provides advice to theMinisters
of Health on all aspects of vaccination. Under recent legislation a recommendation from the Committee
confers the right to the vaccine concerned to the population of England Wales. A critical aspect of both
advice and recommendations is that the vaccination is shown to reach a cost-effectiveness threshold.
This usually requires sophisticated mathematical modelling and economics.
© 2010 Elsevier Ltd. Open access under CC BY-NC-ND license. . Description and background
The Joint Committee on Vaccination and Immunisation (JCVI)
s a Standing Advisory Committee. It was originally an advisory
oard for polio immunisation that became the JCVI in 1963. The
CVI in its current statutory form was established by the National
ealth Service (NHS) (Standing Advisory Committees) Order 1981
SI 1981/597) made under what are now provisions of the NHS Act
006 and the NHS (Wales) Act 2006. Statutory functions of the JCVI
xtend to England and Wales.
The committee currently consists of 17 members with each
ember representing a different professional discipline although
ll professional members must have speciﬁc knowledge of vacci-
ation. Thus there are a general hospital paediatrician, a paediatric
eurologist, an adult infectious disease physician, a paediatrician
ith interest in infectious disease, a community paediatrician, a
urse (currently two), a public health physician, a general prac-
itioner, an epidemiologist, an immunologist, a bacteriologist, a
irologist and a lay person plus a member from each of Scotland
a public health physician), Wales (a public health physician) and
orthern Ireland (a paediatrician). An economist is currently being
ecruited because of the increasing importance of economic evalu-
tion. Members are recruited through national advertisement and
he selection made by an independent body, the Appointments
ommission. The Chairman is selected by committee members
rom amongst themselves. The lengths of appointments are deter-
Abbreviations: HPA, Health Protection Agency; JCVI, Joint Committee on Vacci-
ation and Immunisation; MHRA, Medicines and Health Care Regulatory Agency;
HS, National Health Service; NIBSC, National Institute of Biological Standards and
ontrol; QALY, Quality Adjusted Life Year; UK, United Kingdom.
∗ Tel.: +44 020 7927 2272; fax: +44 020 7637 4314.
E-mail address: Andy.Hall@lshtm.ac.uk.
264-410X © 2010 Elsevier Ltd.
oi:10.1016/j.vaccine.2010.02.034
Open access under CC BY-NC-ND license. mined using the Code of Practice from the Commissioner for Public
Appointments. The Chairman and members are not remunerated
but payment of expenses is made for attendance at meetings. The
Committeemeets three timesperyearundernormal circumstances
although two additional meetings to discuss pandemic inﬂuenza
have been necessary this year (2009).
The secretariat to the committee is provided by the Immunisa-
tion section of the Department of Health. The Agenda is agreed
between the Chairman and the secretariat and includes issues
raised by members, through letters to the committee and by the
Ministers of Health.
2. Role of the committee in policy formulation
Until recently the advice that the committee provided to Min-
isters was just that advice. However, relevant provisions of the
NHS Constitution were enacted via Regulations which came into
force on 1st April 2009. The Regulations specify that the public in
England have the right to receive vaccinations as speciﬁed in any
“Recommendation” of the committee that relates to a newnational
vaccination programme or to changes to an existing national vac-
cination programme. The Recommendation must be on a question
speciﬁcally referred by the Secretary of State, be based on an
assessment which demonstrates cost-effectiveness and not relate
to travel or occupational health. All other decisions of the JCVI are
merely advisory.
3. Terms of reference and processes of meetingsThe JCVI adopted new terms of reference at their meeting on
17th June 2009. They are (in part): “To advise the Secretary of State
for Health and Welsh Ministers on matters relating to communi-
cable diseases, preventable and potentially preventable through
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Table 1
Haemophilus inﬂuenzae type b (Hib) booster campaign 2007.
1. Routine surveillance showed an increase in Hib disease greater than
expected in children aged 3–4 years and over
2. The committee considered adding a booster dose to the pre-school
Diphtheria-Pertussis-Tetanus (DPT) dose
3. It was estimated that 50 cases of disease and 2 deaths could be
prevented but the cost-effectiveness exceeded the threshold
4. Nevertheless the committee advised that a booster campaign should
be conducted
5. This advice was accepted by the Government
6. However it necessitated that for the period of the campaign the
vaccine used was changed from Diphtheria-Tetanus-acellular
Pertussis (DTaP)/inactivated polio vaccine (IPV) or reduced dose
diphtheria-Tetanus-acellular Pertussis (dTaP)/IPV to DTaP/IPV/Hib
or for older children Hib-Meningococcal C vaccine
7. This required the “off-label” use of these vaccines (i.e. outside the
ages that they are licensed for
8. On the basis of evidence the committee recommended this and that
the evidence was published on the website (http://www.dh.gov.uk/
prod consum dh/groups/dh digitalassets/@dh/@ab/documents/digitalasset/A.J. Hall / Vaccin
accination and immunisation”. The JCVI’s statutory functions do
ot relate to Scotland or Northern Ireland although their Minis-
ers may choose to accept its advice. The role of the committee in
ltimate decision making is discussed further below.
There is a JCVI code of practice for members which is pub-
ished on the committee website (http://www.dh.gov.uk/ab/JCVI/
ndex.htm), however a revised Code of Practice and JCVI Protocol
re in development. At each meeting all members must declare
ny potential conﬂicts of interest and a register of such interests is
aintained and published on thewebsite. These potential conﬂicts
re classiﬁed as personal or non-personal. Personal conﬂicts arise
here the individualhas themselves receivedmoney for consultan-
ies with industry, fee paid work where industry pays the member
n cash or kind or where the members holds shares in a company
actual sums of money are not given in the declaration). Indus-
ry here refers to companies, partnerships of individuals who are
nvolved with the manufacture, promotion or supply of vaccines,
rade associations representing such companies or similar bodies
ngaged in research and development or marketing of products
nder consideration by the committee. Non-personal conﬂicts are
hose where payment beneﬁts a department for which a member
s responsible but is not received by the member personally. The
sual examples are industry funded grants and fellowships, pay-
ents of salaries for staff or sponsorship of research by industry.
hese are all considered relevant if they occurred in the 12months
rior to the meeting or are planned to occur in the future.
These potential conﬂicts of interest are further divided into
hose that are speciﬁc to the vaccine or product under discussion
nd non-speciﬁcwhere they relate to a different vaccine or product
ade by the relevant company.
During the meeting members with a personal speciﬁc interest
re asked to leave the roomduring discussion and decisionmaking.
hose with a personal non-speciﬁc interest take part in the dis-
ussion but not in the decision making. Those with non-personal
peciﬁc interests can participate in the discussion, unless the chair-
an rules otherwise but do not take part in decision making and
hosemembers with non-personal, non-speciﬁc interests take part
n the discussion and decision making.
The committee carries out horizon scanning—mainly aimed at
dentifying vaccines which are likely to be licensed in the next 3–5
ears. This allows them to advise on the development of appro-
riate surveillance in advance of licensure and any research which
ay be needed to facilitate decision making. For example if costs
f a potentially vaccine preventable illness need to be collected or
he current burden of disease to be estimated.
The committee frequently has to consider changes to the vac-
ination schedules—for example where new evidence suggests a
hange in dose interval or timing would be beneﬁcial. Similarly
here may be changes in indications for vaccines due to new evi-
ence and the committee provides advice on this. As part of its
ork the committee considers data on vaccine coverage and may
rovide advice in relation to this. However the committee has no
ole in running the immunisation programmes.
In addition the committee reviews informationonpotential vac-
ine adverse events including published studies from the global
iterature, reports of studies speciﬁcally carried out in the United
ingdom (UK), the routine surveillance of adverse reactions car-
ied out by the Health Protection Agency (HPA) and reports from
he surveillance system of the Medicines and Healthcare Regula-
oryAgency (MHRA). The committeeuses this information toweigh
isks and beneﬁts in its decision making but has no regulatory role
n relation to vaccines (see case study on the Hib booster campaign
n Table 1).
The work of the committee which attracts the most attention
s related to newly licensed vaccines. This is discussed in the next
wo sections.dh 094741.pdf)
4. Development of recommendations and basis for decision
making
Where a new vaccine or an alteration to the routine schedule
is to be discussed by the main committee the ﬁrst step taken is
to establish an expert sub-committee. This has a member of the
main JCVI as the chairman and any additional members of the
main committeewho have particular expertise relevant to the vac-
cination being considered. Other members of this sub-committee
are then recruited with relevant expertise from academia, govern-
ment agencies, etc. This is done to ensure that all of the necessary
disciplines are represented—e.g. laboratory science, clinical, epi-
demiological, modelling and economics. These sub-committee
members also have to make declarations of potential conﬂicts of
interest and the same procedures in handling these apply. The
sub-committee will then meet perhaps two or three times to
review the evidence available and where appropriate to provide
advice on parameters for modelling and economics. It will for-
mulate advice on a recommendation which is then passed to the
main committee. In the meantime any cost-effectiveness mod-
elling that has been necessary will go out to peer review. This
review is done by national and international experts—both in
economic modelling and in the disease speciﬁc area. These ref-
eree reports are then sent to the group who carried out the
cost-effectiveness estimation and they respond—either with a
rebuttal of the comments or with a modiﬁcation of the esti-
mates.
All of these reports then come to the main committee. It
then chooses to accept or modify the sub-committee recom-
mendation. On occasion it may require a further modiﬁcation
of the economic analysis or of the underlying question being
addressed.
Finally the JCVI makes a recommendation or provides advice.
A recommendation applies when the question has been asked of
the committee speciﬁcally by the Secretary of State for Health
and it applies to universal vaccination. This has speciﬁc implica-
tions as described above. Advice, rather than a recommendation,
is provided when such a question has not been asked, for exam-
ple where it is a change in indication or a modiﬁcation of existing
advice—or where the vaccination concerned is occupational or
for travellers. These latter two are not funded centrally by the
government—either the employer or the traveller themselvesmust
pay for the vaccine. In these cases the advice from the JCVI is simply
guidance.
A56 A.J. Hall / Vaccine 28S (
Table 2
Developing Human Papilloma Virus (HPV) vaccine advice.
1. New vaccines against HPV 16 and 18 were about to become available,
there were two potential vaccines: one bivalent and one quadrivalent
including HPV types that cause genital warts
2. Joint Committee on Vaccination and Immunisation (JCVI) established a
sub-committee of experts on HPV
3. Sub-committee reviewed published evidence, data from manufacturers
and worked with Health Protection Agency (HPA) surveillance and
infectious disease modellers to develop advice (3 meetings)
4. Sub-committee identiﬁed missing information
5. HPA collected data to ﬁll gaps on age speciﬁc information on acquisition
of HPV types 16 and 18 by single years of age from 12- to 25-year-old
girls [1]
6. HPA collected data on costs of treatment of genital warts [2]
7. HPA developed cost-effectiveness model of HPV vaccination in the
United Kingdom [3]
8. Cost-effectiveness model refereed, modiﬁed and submitted to main JCVI
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the extensive training now ongoing should resolve this limitation9. JCVI agreed recommendation:
http://www.dh.gov.uk/prod consum dh/groups/dh digitalassets/@dh/@ab/
documents/digitalasset/dh 094739.pdf
. Role played by economic evaluations and other ﬁnancial
ssues in decision making
Cost-effectiveness is the cornerstone of decision making where
niversal vaccination of the population is concerned since the costs
f the vaccination are borne by the Government through central
rocurement of vaccines. The guidelines used by the committee
re that the vaccine should result in a cost of less than £20–30,000
er Quality Adjusted Life Year (QALY) gained. This is used across
he health policy making ﬁeld in the UK to ensure a balance in
reventative and treatment options available to the public. The
evelopment of the cost-effectiveness data requires a combination
f economic cost data onvaccine, vaccinedelivery, illness anddeath
nd mathematical modelling to capture potential herd immunity
ffects. The perspective used is that of the NHS—so no societal costs
re included (such as loss of parental time at work). This leads
o some less serious infections, such as rotavirus and chickenpox,
here the burden fall largely on the family not reaching the cost-
ffective threshold. The committee plays no role in procurement of
accine. It does not know the price of vaccines offered to the UK
or what is ﬁnally agreed by the procurement process since this
s commercially conﬁdential (see case study on the HPV vaccine
dvice in Table 2).
. Role of manufacturers, and other private and
rofessional interest groups
Manufacturers do not attend JCVI nor sub-committees. They are
n regular contact with the secretariat in the Department of Health
nd havemeetings to discuss developments and relationships. JCVI
as recently introduced the practice of asking manufacturers for
nformation directly when carrying out horizon scanning in order
o make this as complete as possible. When sub-committees meet
o discuss possible advice the industry is asked to provide writ-
en information. This often includes unpublished and commercially
ensitive information. Industry has expressed a desire to havemore
nput to the process and speciﬁcally to attend and present at sub-
ommittee meetings. However JCVI has so far not agreed to this.
espite this situation some of the public and news media perceive
he committee as too inﬂuenced by the Pharmaceutical industry.
his perceptionarises fromthe fact that thepublicly listedpotential
onﬂicts of interest include funding for research from commer-
ial organisations. Although these potential conﬂicts of interest are
arefully handled in meetings to ensure that they do not inﬂuence
he advice provided.2010) A54–A57
Meetings of the JCVI and of sub-committees are closed. How-
ever observers are invited, and regularly attend, from the devolved
administrations in Wales, Scotland and Northern Ireland as well
as on occasion from Jersey and the Isle of Man. Also invited
as observers are representatives of the HPA, Health Protection
Scotland (HPS), the National Institute of Biological Standards and
Control (NIBSC which since April has been part of the HPA), MHRA.
The HPA is responsible for surveillance in England of vaccine pre-
ventable disease and carries out extensive work on the assessment
of vaccines both through observational studies and trials. In addi-
tion HPA carries out routine surveillance of adverse reactions with
speciﬁc research studies where necessary. This work is often done
in conjunction with the MHRA. HPS fulﬁls a similar role for Scot-
land. NIBSC is responsible for the testing and clearance of batches
of vaccine imported to the country and thus has exceptional knowl-
edgeandexperiencewith laboratory aspects of vaccines. TheMHRA
is responsible for monitoring of adverse reactions to medicines
including vaccines. They regularly report to the committee on these
data. Members of the public or representatives of public interest
groups are not admitted to JCVI or sub-committee meetings.
7. Communication activities and training practices
The agenda for JCVI meetings is placed on the public website
2 weeks in advance of each meeting. The minutes of each meet-
ing are also placed on the website within 6 weeks of each meeting
along with minutes of sub-committee meeting once ratiﬁed by the
sub-committee and JCVI. All JCVI advice is collaged into a publica-
tion – Immunisation against Infectious Disease (“the Green Book”).
This is edited by the Department of Health and members of the
Immunisation Division of the HPA. Although it is physically pub-
lished irregularly (the last edition was in 2006) every alteration
to the advice is posted on the website and a “patch” is provided
which can be printed and pasted into the hard copy of the book.
The chairman of the committee speaks on the work of the commit-
tee at meetings of Immunisation Coordinators in England annually
and when requested in Scotland, Wales and Northern Ireland.
8. Problems encountered, limitations and future
developments
The committee functionswell and ingeneral hasnothad speciﬁc
problems. A general concern has beenhowweensure that the com-
mittee keeps up to date with the latest evidence. There are many
vaccines involved in the programme and the committeewould like
to see any relevant evidence that might affect existing policy on
these at each meeting. However the volume of work in carrying
out rolling systematic reviews makes this impossible. Of course
the committee members are themselves all involved in vaccina-
tion – either research or programme delivery – and the secretariat
in Department of Health are constantly exposed to new informa-
tion, therefore the committee relies on these sources to keep the
committee up to date.
The committeewould ideally like each cost-effectiveness analy-
sis to be carried out by at least two groups using differentmethods.
This has occurredwith thework onmodelling of inﬂuenzaAH1N1v
epidemiologyandvaccination.However todo this for eachquestion
facing the committee is beyond the infectious disease modelling
capacity of the UK—although the UK is very well supplied with
such expertise. The growth of interest in this area of science andin time.
A result of the changes resulting from the NHS Constitution is
that we need to strengthen the committee in economics and infec-
tious disease modelling expertise. In addition the committee has
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een criticised for a lack of openness—this is a topic the committee
egularly reviews and plans to take steps to improve transparency
n the near future.
. Summary and conclusions
JCVI is an independent committee which advises Ministers of
ealth in the UK on vaccine policy. It has been successful in that
heGovernmenthas, to date, implemented the advice.However the
rocesses of the committee are constantly being criticised (unfairly
n the opinion of the committee, which is strongly protective of its
ndependence and regards it as vital to its role) either by the vaccine
ndustry for not allowing them sufﬁcient access to the committee
r by the public for being too inﬂuenced by the vaccine industry. In
ddition there is constant pressure to increase openness and trans-
arency in the committee activities. This is likely to lead to changes
[
[2010) A54–A57 A57
in thenear future, althoughensuring that any changesmade arenot
detrimental to its role and function.
Conﬂict of interest statement
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